News

Pharmabiz21h
Prima Mente launches Pleiades, a human epigenome foundation model with applications for Alzheimer’s disease
Prima Mente launches Pleiades, a human epigenome foundation model with applications for Alzheimer’s disease: London Saturday, July 19, 2025, 18:00 Hrs [IST] San Francisco and Lo ...
Pharmabiz22h
Repare Therapeutics signs exclusive global licensing agreement with Debiopharm International for lunresertib
Repare Therapeutics signs exclusive global licensing agreement with Debiopharm International for lunresertib: Cambridge, Massachusetts Saturday, July 19, 2025, 17:00 Hrs [IST] Rep ...
Pharmabiz22h
Genascence’s GNSC-001 for knee osteoarthritis receives US FDA regenerative medicine advanced therapy designation
Genascence’s GNSC-001 for knee osteoarthritis receives US FDA regenerative medicine advanced therapy designation: Palo Alto, California Saturday, July 19, 2025, 16:30 Hrs [IST] ...
Pharmabiz23h
Nanochon gets Health Canada approval for first in human investigation to assess safety and performance of its Chondrograft system
Nanochon gets Health Canada approval for first in human investigation to assess safety and performance of its Chondrograft system: Washington Saturday, July 19, 2025, 16:00 Hrs [I ...
Pharmabiz23h
Synendos Therapeutics appoints Dr. George Garibaldi as CMO to enhance phase 2 clinical development of its lead drug asset SYT-510
Synendos Therapeutics appoints Dr. George Garibaldi as CMO to enhance phase 2 clinical development of its lead drug asset SYT-510: Basel, Switzerland Saturday, July 19, 2025, 15:3 ...